Prevalence of HI-PEITHO–Eligible Patients in the RIETE Registry and Simulated Population-Level Projections for Ultrasound-Facilitated Catheter-Directed Fibrinolysis
Year: 2026
Type: article
Abstract: Extract Normotensive acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and elevated cardiac biomarkers (ESC intermediate-high risk; AHA/ACC categories C3–D2) is associated with a substantial risk of adverse outcomes. [1, 2] Reported 7-day mortality ranges from 1–2%, while clinical deterioration requiring escalation of care occurs in approximately 5–10% of patients treated with anticoagulation alone. [3, 4] Addressing the longstanding debate regarding the optimal management of intermediate-high-risk PE, the recently published Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO) trial enrolled a risk-enriched cohort with features of cardiorespiratory compromise.
Source: ERJ Open Research
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
OpenAlex ID: W7236723401
